OPTIMAAL Does the dose make the medicine Eric

  • Slides: 14
Download presentation
OPTIMAAL: Does the dose make the medicine? Eric J Topol MD Provost and Chief

OPTIMAAL: Does the dose make the medicine? Eric J Topol MD Provost and Chief Academic Officer Chairman, Department of Cardiovascular Medicine The Cleveland Clinic Foundation Cleveland, OH Robert M Califf MD Professor of Medicine Associate Vice Chancellor for Clinical Research Director, Duke Clinical Research Institute Duke University Medical Center Durham, NC Thumbs up/Thumbs down – Oct 2002

OPTIMAAL ACE inhibitor vs ARB Patients with complicated acute MI with heart failure or

OPTIMAAL ACE inhibitor vs ARB Patients with complicated acute MI with heart failure or significant systolic dysfunction are at high risk OPTIMAAL pitted an angiotensin receptor blocker (losartan) vs standard ACE inhibitor (captopril) in these patients Thumbs up/Thumbs down – Oct 2002 Califf

OPTIMAAL Trial design Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan

OPTIMAAL Trial design Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) PI: Kenneth Dickstein • 5477 patients. • Acute MI. • Losartan 50 mg once daily vs captopril 50 mg 3 times daily. • Primary end point: all-cause mortality at 2. 7 years' follow-up. Thumbs up/Thumbs down – Oct 2002

OPTIMAAL Results p=0. 069 Thumbs up/Thumbs down – Oct 2002 p=0. 722 p=0. 032

OPTIMAAL Results p=0. 069 Thumbs up/Thumbs down – Oct 2002 p=0. 722 p=0. 032 p=0. 587 Lancet 360: 752 -760

OPTIMAAL Head-to-head trial Give credit to Merck for doing a head -to-head trial "We

OPTIMAAL Head-to-head trial Give credit to Merck for doing a head -to-head trial "We always learn a lot from these trials, even though in the old days people called them 'not creative, ' 'boring, ' terms like that. " Thumbs up/Thumbs down – Oct 2002 Califf

OPTIMAAL Titration phase Separation of the mortality curves all occurs in the first month,

OPTIMAAL Titration phase Separation of the mortality curves all occurs in the first month, during the titration phase After the first month, the curves are the same except for the discontinuation losartan -- 17% captopril -- 23% Thumbs up/Thumbs down – Oct 2002 Califf

OPTIMAAL Mortality with losartan p=0. 069 Thumbs up/Thumbs down – Oct 2002 p=0. 016

OPTIMAAL Mortality with losartan p=0. 069 Thumbs up/Thumbs down – Oct 2002 p=0. 016 p=0. 206

OPTIMAAL Questions Is that early remodeling phase very important in terms of reninangiotensin system

OPTIMAAL Questions Is that early remodeling phase very important in terms of reninangiotensin system inhibition? Is it just a dosing issue? "If you get the wrong dose, maybe the drug is not going to be as good. " Thumbs up/Thumbs down – Oct 2002 Califf

OPTIMAAL Importance of dosing You shouldn't start a big trial until you know what

OPTIMAAL Importance of dosing You shouldn't start a big trial until you know what the ideal dose is "This study would suggest that ACE inhibition is still the anchor therapy. " Need to piece together clues from many trials Thumbs up/Thumbs down – Oct 2002 Topol

OPTIMAAL LIFE: Primary composite end point Proportion of patients with first event (%) 16

OPTIMAAL LIFE: Primary composite end point Proportion of patients with first event (%) 16 Study Month Losartan (n) Atenolol (n) Intention-to-treat 14 Atenolol 12 Losartan 10 8 6 4 Adjusted risk reduction 13. 0%, p=0. 021 Unadjusted risk reduction 14. 6%, p=0. 009 2 0 0 4605 4588 6 4524 4494 12 4460 4414 18 4392 4349 24 4312 4289 Thumbs up/Thumbs down – Oct 2002 30 4247 4205 36 4189 4135 42 4112 4066 48 4047 3992 54 3897 3821 60 1889 1854 66 901 876 Dahlof et al. Lancet 2002; 359: 995 -1003

OPTIMAAL Changing the wrong dose "I think sometimes we end up with the wrong

OPTIMAAL Changing the wrong dose "I think sometimes we end up with the wrong dose just because it's too much trouble to go through all the decisions to get it changed. " Califf "That's unfortunate, really. When you put thousands of patients through an experiment, you would hope that you're giving it your best shot. " Topol Thumbs up/Thumbs down – Oct 2002

OPTIMAAL TARGET dosing No one knows if the dosing in TARGET was incorrect, even

OPTIMAAL TARGET dosing No one knows if the dosing in TARGET was incorrect, even if that is a possible, plausible explanation of the results Tirofiban: 10µg/kg bolus, 0. 15 µg/kg per min infusion (18 - to 24 -hr duration) Abciximab: 0. 25 µg/kg bolus, 0. 125 µg/kg per min infusion to maximum 10 µg/min (12 -hr duration) Thumbs up/Thumbs down – Oct 2002

OPTIMAAL Multiple dose trials It can be months to get anything changed in a

OPTIMAAL Multiple dose trials It can be months to get anything changed in a protocol with major trials "I'm afraid that my view is the only way to deal with this is to do large trials with several doses. . But we'd just run up against the practical difficulty of sample size and what it takes to get there. " Thumbs up/Thumbs down – Oct 2002 Califf

OPTIMAAL Future trials should tell us a lot about dose for ARB vs ACE

OPTIMAAL Future trials should tell us a lot about dose for ARB vs ACE inhibitors: VALIANT (valsartan in acute myocardial infarction) CHARM (candesartan in heart failure assessment of reduction in mortality) Thumbs up/Thumbs down – Oct 2002